Free Trial

Nevro (NVRO) Stock Forecast & Price Target

Nevro logo
$4.32 -0.23 (-5.05%)
(As of 04:28 PM ET)

Nevro - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
11
Buy
0

Based on 14 Wall Street analysts who have issued ratings for Nevro in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 14 analysts, 3 have given a sell rating, and 11 have given a hold rating for NVRO.

Consensus Price Target

$9.10
110.65% Upside
According to the 14 analysts' twelve-month price targets for Nevro, the average price target is $9.10. The highest price target for NVRO is $23.00, while the lowest price target for NVRO is $5.50. The average price target represents a forecasted upside of 110.65% from the current price of $4.32.
Get the Latest News and Ratings for NVRO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Nevro and its competitors.

Sign Up

NVRO Analyst Ratings Over Time

TypeCurrent Forecast
11/27/23 to 11/26/24
1 Month Ago
10/28/23 to 10/27/24
3 Months Ago
8/29/23 to 8/28/24
1 Year Ago
11/27/22 to 11/27/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
4 Buy rating(s)
Hold
11 Hold rating(s)
11 Hold rating(s)
11 Hold rating(s)
7 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$9.10$10.55$10.63$27.50
Forecasted Upside110.65% Upside130.25% Upside84.49% Upside66.57% Upside
Consensus Rating
Reduce
Reduce
Reduce
Hold

NVRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nevro Stock vs. The Competition

TypeNevroMedical CompaniesS&P 500
Consensus Rating Score
1.79
2.80
2.50
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside109.68% Upside24,609.58% Upside6.90% Upside
News Sentiment Rating
Positive News

See Recent NVRO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/12/2024JMP Securities
2 of 5 stars
D. Turkaly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
11/12/2024Canaccord Genuity Group
1 of 5 stars
 Lower TargetHold ➝ Hold$8.00 ➝ $7.00+13.27%
11/12/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingSector Perform ➝ Sector Perform$7.00 ➝ $7.00+10.41%
11/12/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$7.00 ➝ $6.00+12.57%
11/12/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$5.00 ➝ $6.00+12.57%
10/1/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$6.89 ➝ $6.00+13.64%
This Crisis Could Be Worse Than 2008 (Ad)

Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.

In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street.
8/8/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$10.00 ➝ $5.50+13.17%
8/8/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
8/7/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
8/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Treybeck
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeEqual Weight ➝ Underweight$13.00 ➝ $5.50-36.71%
7/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $9.00-4.26%
4/11/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$20.00 ➝ $16.00+20.30%
2/22/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:16 PM ET.


NVRO Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Nevro is $9.10, with a high forecast of $23.00 and a low forecast of $5.50.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 sell ratings and 11 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NVRO shares.

According to analysts, Nevro's stock has a predicted upside of 110.65% based on their 12-month stock forecasts.

Nevro has been rated by research analysts at Canaccord Genuity Group, Citigroup, JMP Securities, Piper Sandler, Robert W. Baird, and Royal Bank of Canada in the past 90 days.

Analysts like Nevro less than other "medical" companies. The consensus rating for Nevro is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVRO compares to other companies.


This page (NYSE:NVRO) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners